Cargando…
New insights into the mode of action of the lantibiotic salivaricin B
Salivaricin B is a 25 amino acid polycyclic peptide belonging to the type AII lantibiotics and first shown to be produced by Streptococcus salivarius. In this study we describe the bactericidal mode of action of salivaricin B against susceptible Gram-positive bacteria. The killing action of salivari...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985645/ https://www.ncbi.nlm.nih.gov/pubmed/27526944 http://dx.doi.org/10.1038/srep31749 |
_version_ | 1782448093817470976 |
---|---|
author | Barbour, Abdelahhad Tagg, John Abou-Zied, Osama K. Philip, Koshy |
author_facet | Barbour, Abdelahhad Tagg, John Abou-Zied, Osama K. Philip, Koshy |
author_sort | Barbour, Abdelahhad |
collection | PubMed |
description | Salivaricin B is a 25 amino acid polycyclic peptide belonging to the type AII lantibiotics and first shown to be produced by Streptococcus salivarius. In this study we describe the bactericidal mode of action of salivaricin B against susceptible Gram-positive bacteria. The killing action of salivaricin B required micro-molar concentrations of lantibiotic whereas the prototype lantibiotic nisin A was shown to be potent at nano-molar levels. Unlike nisin A, salivaricin B did not induce pore formation or dissipate the membrane potential in susceptible cells. This was established by measuring the fluorescence of the tryptophan residue at position 17 when salivaricin B interacted with bacterial membrane vesicles. The absence of a fluorescence blue shift indicates a failure of salivaricin B to penetrate the membranes. On the other hand, salivaricin B interfered with cell wall biosynthesis, as shown by the accumulation of the final soluble cell wall precursor UDP-MurNAc-pentapeptide which is the backbone of the bacterial peptidoglycan. Transmission electron microscopy of salivaricin B-treated cells showed a reduction in cell wall thickness together with signs of aberrant septum formation in the absence of visible changes to cytoplasmic membrane integrity. |
format | Online Article Text |
id | pubmed-4985645 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49856452016-08-22 New insights into the mode of action of the lantibiotic salivaricin B Barbour, Abdelahhad Tagg, John Abou-Zied, Osama K. Philip, Koshy Sci Rep Article Salivaricin B is a 25 amino acid polycyclic peptide belonging to the type AII lantibiotics and first shown to be produced by Streptococcus salivarius. In this study we describe the bactericidal mode of action of salivaricin B against susceptible Gram-positive bacteria. The killing action of salivaricin B required micro-molar concentrations of lantibiotic whereas the prototype lantibiotic nisin A was shown to be potent at nano-molar levels. Unlike nisin A, salivaricin B did not induce pore formation or dissipate the membrane potential in susceptible cells. This was established by measuring the fluorescence of the tryptophan residue at position 17 when salivaricin B interacted with bacterial membrane vesicles. The absence of a fluorescence blue shift indicates a failure of salivaricin B to penetrate the membranes. On the other hand, salivaricin B interfered with cell wall biosynthesis, as shown by the accumulation of the final soluble cell wall precursor UDP-MurNAc-pentapeptide which is the backbone of the bacterial peptidoglycan. Transmission electron microscopy of salivaricin B-treated cells showed a reduction in cell wall thickness together with signs of aberrant septum formation in the absence of visible changes to cytoplasmic membrane integrity. Nature Publishing Group 2016-08-16 /pmc/articles/PMC4985645/ /pubmed/27526944 http://dx.doi.org/10.1038/srep31749 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Barbour, Abdelahhad Tagg, John Abou-Zied, Osama K. Philip, Koshy New insights into the mode of action of the lantibiotic salivaricin B |
title | New insights into the mode of action of the lantibiotic salivaricin B |
title_full | New insights into the mode of action of the lantibiotic salivaricin B |
title_fullStr | New insights into the mode of action of the lantibiotic salivaricin B |
title_full_unstemmed | New insights into the mode of action of the lantibiotic salivaricin B |
title_short | New insights into the mode of action of the lantibiotic salivaricin B |
title_sort | new insights into the mode of action of the lantibiotic salivaricin b |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985645/ https://www.ncbi.nlm.nih.gov/pubmed/27526944 http://dx.doi.org/10.1038/srep31749 |
work_keys_str_mv | AT barbourabdelahhad newinsightsintothemodeofactionofthelantibioticsalivaricinb AT taggjohn newinsightsintothemodeofactionofthelantibioticsalivaricinb AT abouziedosamak newinsightsintothemodeofactionofthelantibioticsalivaricinb AT philipkoshy newinsightsintothemodeofactionofthelantibioticsalivaricinb |